May 2022 | Pfizer COVID Pill added to PBS | Australia

Commencing 1 May 2022 Anti-COVID Pill added to the PBS
- Lagevrio (Molnupiravir), Paxlovid
"Australians will only pay $42.50 per script or $6.80 if using concession card"

Clinical criteria for PBS listed Lagevrio and Paxlovid:

* People 65 years or older with two additional high-risk factors for developing severe disease,
* People 75 years or older with one additional high-risk factor for developing severe disease,
* Moderately to severely immunocompromised people irrespective of vaccination status, and
* Aboriginal and Torres Strait Islander people aged 50 years or older with two additional high-risk factors for developing severe disease.

Priority communities
Initial distribution of the oral treatments by the Australian Government was prioritised to those with the highest clinical need including:

* people living in residential aged care facilities
* rural and remote communities
* Aboriginal and Torres Strait Islander people
* people with a disability, especially in a supported living setting.

Articles:
-Australia-
https://www.theguardian.com/australia-news/2022/feb/10/covid-19-pills-vulnerable-and-unvaccinated-australians-to-be-prioritised-for-new-oral-treatments

Drug Info:
-Australia-
https://www.nps.org.au/coronavirus/antiviral-treatments-for-covid-19
https://www.health.gov.au/health-alerts/covid-19/treatments/oral

PBS Listing:
-Australia-
https://www.pbs.gov.au/info/news/2022/04/paxlovid-nirmatrelvir-and-ritonavir-pbs-listing
https://www.pbs.gov.au/info/news/2022/03/lagevrio-molnupiravir-pbs-listing
-USA-
https://www.pbs.org/newshour/health/pfizer-pill-becomes-first-home-covid-19-treatment-authorized-in-the-u-s